The First FDA-Approved Mesothelioma Drug in 15 Years
On October 2, 2020, the first FDA-approved mesothelioma drug in 15 years hit the market. They approved a new combination…
-
-
Maximizes Your Immune Cell Response with High-Intensity Exercise
There is an increasing role of high-intensity exercise training in cancer care. Evidence suggests that exercise can reduce side effects… -
New Drug Targeting Fibrosis may Help Mesothelioma Patients
Targeting fibrosis has therapeutic benefits in mesothelioma. Most drugs have limited effects in difficult-to-treat cancers such as mesothelioma. Often this… -
Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused… -
Clinical Trial Participation: Perspectives from Mesothelioma Patients and Caregivers
Clinical trial participation is a common topic for mesothelioma patients and their caregivers. Treatment options for mesothelioma are increasing. This… -
First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural… -
Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment
Immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. Malignant pleural mesothelioma is an aggressive disease. Asbestos exposure… -
Radiation Therapy for Mesothelioma Patients: Value and Timing
The value and safety of radiation therapy for mesothelioma patients are promising. Oncologists from the Fox Chase Cancer Center released… -
Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma
Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year… -
